Lithuania vs Oman: Previously treated cases tested for RR-/MDR-TB
Lithuania
100.0%
in 2024
Oman
100.0%
in 2024
Lithuania rank
1st
Oman rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Lithuania
- Oman
How they compare
Lithuania currently reports 100.0% against 100.0% in Oman, a difference of 0.0%.
The two have swapped places 4 times across 19 shared years of data; in 2005 it was Oman ahead.
Lithuania ranks 1st and Oman ranks 1st of 180 countries.
Across the 3 decades both report, Lithuania averaged higher in 1 and Oman in 1.
Head to head by decade
| Decade | Lithuania | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 98.4% | 100.0% | 1.6% | Oman |
| 2010s | 100.0% | 96.9% | 3.1% | Lithuania |
| 2020s | 100.0% | 100.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Lithuania or Oman?
- Lithuania, at 100.0% against 100.0% in Oman as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Lithuania and Oman?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Oman?
- 19 years are reported by both, from 2005 to 2024.
- How do Lithuania and Oman rank globally for previously treated cases tested for rr-/mdr-tb?
- Lithuania ranks 1st and Oman ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.